Leading the Way in Life Science Technologies

GEN Exclusives

More »
Insight & Intelligence™

Related to FDA Green-Lights Novartis’ Tasigna as First-Line Therapy for Newly Diagnosed Ph+ CML

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »